利索-全球专利检索

  1. Login
  2. Sign Up

Search Results

8 records (took 0.028 seconds)

    Cysteine engineered anti-MUC16 antibodies and antibody drug conjugates
    1.
    发明授权
    Cysteine engineered anti-MUC16 antibodies and antibody drug conjugates 有权
    半胱氨酸改造的抗MUC16抗体和抗体药物偶联物

    公开(公告)号：US07723485B2

    公开(公告)日：2010-05-25

    申请号：US12116457

    申请日：2008-05-07

    Applicant: Jagath R. Junutula ,  William Mallet

    Inventor： Jagath R. Junutula ,  William Mallet

    IPC: C07K16/00 ,  C12P21/08 ,  C07K17/00 ,  C07K17/14 ,  A61K39/395 ,  A61K39/00 ,  G01N33/53 ,  G01N33/574 ,  C12P21/04

    CPC classification number: C07K16/28 ,  A61K47/6803 ,  A61K47/6849 ,  A61K51/1027 ,  A61K2039/505 ,  C07K2317/624 ,  C07K2317/71 ,  C07K2317/72 ,  C07K2319/55

    Abstract: Cysteine engineered anti-MUC16 antibodies are engineered by replacing one or more amino acids of a parent anti-MUC16 antibody with non cross-linked, reactive cysteine amino acids. Methods of design, preparation, screening, and selection of the cysteine engineered anti-MUC16 antibodies are provided. Cysteine engineered anti-MUC16 antibodies (Ab) are conjugated with one or more drug moieties (D) through a linker (L) to form cysteine engineered anti-MUC16 antibody-drug conjugates having Formula I: Ab-(L-D)p  I where p is 1 to 4. Diagnostic and therapeutic uses for cysteine engineered antibody drug compounds and compositions are disclosed.

    Abstract translation: 通过用非交联的反应性半胱氨酸氨基酸替代亲本抗MUC16抗体的一个或多个氨基酸来工程化半胱氨酸改造的抗MUC16抗体。 提供了设计，制备，筛选和选择半胱氨酸改造的抗MUC16抗体的方法。 半胱氨酸改造的抗MUC16抗体（Ab）通过接头（L）与一个或多个药物部分（D）缀合以形成具有式I：Ab-（LD）p I的半胱氨酸改造的抗MUC16抗体 - 药物共轭物，其中p 公开了半胱氨酸改造的抗体药物化合物和组合物的诊断和治疗用途。

    CYSTEINE ENGINEERED ANTI-MUC16 ANTIBODIES AND ANTIBODY DRUG CONJUGATES
    3.
    发明申请
    CYSTEINE ENGINEERED ANTI-MUC16 ANTIBODIES AND ANTIBODY DRUG CONJUGATES 有权
    CYSTEINE工程抗MUC16抗体和抗体药物联合

    公开(公告)号：US20080311134A1

    公开(公告)日：2008-12-18

    申请号：US12116457

    申请日：2008-05-07

    Applicant: Jagath R. Junutula ,  William Mallet

    Inventor： Jagath R. Junutula ,  William Mallet

    IPC: A61K39/44 ,  C07K16/00 ,  A61P35/00 ,  G01N33/53

    CPC classification number: C07K16/28 ,  A61K47/6803 ,  A61K47/6849 ,  A61K51/1027 ,  A61K2039/505 ,  C07K2317/624 ,  C07K2317/71 ,  C07K2317/72 ,  C07K2319/55

    Abstract: Cysteine engineered anti-MUC16 antibodies are engineered by replacing one or more amino acids of a parent anti-MUC16 antibody with non cross-linked, reactive cysteine amino acids. Methods of design, preparation, screening, and selection of the cysteine engineered anti-MUC16 antibodies are provided. Cysteine engineered anti-MUC16 antibodies (Ab) are conjugated with one or more drug moieties (D) through a linker (L) to form cysteine engineered anti-MUC16 antibody-drug conjugates having Formula I: Ab-(L-D)p   I where p is 1 to 4. Diagnostic and therapeutic uses for cysteine engineered antibody drug compounds and compositions are disclosed.

    Abstract translation: 通过用非交联的反应性半胱氨酸氨基酸替代亲本抗MUC16抗体的一个或多个氨基酸来工程化半胱氨酸改造的抗MUC16抗体。 提供了设计，制备，筛选和选择半胱氨酸改造的抗MUC16抗体的方法。 半胱氨酸改造的抗MUC16抗体（Ab）通过接头（L）与一个或多个药物部分（D）缀合以形成具有式I的半胱氨酸改造的抗MUC16抗体 - 药物共轭物： “直线公式”end =“lead”？> Ab-（LD）p I <？in-line-formula description =“In-line Formulas”end =“tail”？>其中p为1到4.诊断 并公开了半胱氨酸改造的抗体药物化合物和组合物的治疗用途。

Patent Agency Ranking